Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic lung disease
resulting in increasing shortness of breath, cough, and low oxygen levels as a result of
lung tissue scarring . This will be a single-center randomized, double-blinded,
placebo-controlled study of 20 weeks including1
expand
Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic lung disease
resulting in increasing shortness of breath, cough, and low oxygen levels as a result of
lung tissue scarring . This will be a single-center randomized, double-blinded,
placebo-controlled study of 20 weeks including up to 4 weeks for screening, followed by
12 weeks of oral artesunate treatment across 3 dose levels (dose escalation every 4
weeks), and 4 weeks of a washout (follow-up) period in participants with Idiopathic
Pulmonary Fibrosis (IPF). The primary objective of the study is to evaluate the safety
and tolerability of artesunate at 3 dose levels, and to select the dose(s) to carry
forward into additional clinical testing. The secondary objective includes exploring the
blood biomarkers present in participants with IPF at baseline and to investigate how
those biomarkers change following artesunate treatment. The exploratory objectives
include assessing the changes in the K-BILD and Leicester cough questionnaire scores and
change in pulmonary function after artesunate administration.
Type: Interventional
Start Date: Jan 2027
open study
